Potential markers of disease behavior in acromegaly and gigantism

References

• Melmed S. Acromegaly pathogenesis and treatment. J Clin Invest. 2009;119:3189–3202.
   PubMed Web of Science ®Google Scholar
• Lavrentaki A, Paluzzi A, Wass JA, et al. Epidemiology of acromegaly: review of population studies. Pituitary. 2017;20:4–9.
   PubMed Web of Science ®Google Scholar
• Colao A, Grasso LFS, Giustina A, et al. Acromegaly. Nat Rev Dis Primers. 2019;5:20.
   PubMed Web of Science ®Google Scholar
• Gadelha MR, Kasuki L, Lim DST, et al. Systemic complications of acromegaly and the impact of the current treatment landscape: an update. Endocr Rev. 2019;40:268–332.
   PubMed Web of Science ®Google Scholar
• Katznelson L, Laws ER Jr., Melmed S, et al. Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99:3933–3951.
   PubMed Web of Science ®Google Scholar
• Kasuki L, Wildemberg LE, Gadelha MR. Management of endocrine disease: personalized medicine in the treatment of acromegaly. Eur J Endocrinol. 2018;178:R89–R100.
   PubMedGoogle Scholar
• Puig Domingo M. Treatment of acromegaly in the era of personalized and predictive medicine. Clin Endocrinol (Oxf). 2015;83:3–14.
   PubMed Web of Science ®Google Scholar
• Fernandez-Rodriguez E, Casanueva FF, Bernabeu I. Update on prognostic factors in acromegaly: is a risk score possible? Pituitary. 2015;18:431–440.
   PubMed Web of Science ®Google Scholar
• Caimari F, Korbonits M. Novel genetic causes of pituitary adenomas. Clin Cancer Res. 2016;22:5030–5042.
   PubMed Web of Science ®Google Scholar
• Stratakis CA, Tichomirowa MA, Boikos S, et al. The role of germline AIP, MEN1, PRKAR1A, CDKN1B and CDKN2C mutations in causing pituitary adenomas in a large cohort of children, adolescents, and patients with genetic syndromes. Clin Genet. 2010;78:457–463.
   PubMed Web of Science ®Google Scholar
• Tichomirowa MA, Barlier A, Daly AF, et al. High prevalence of AIP gene mutations following focused screening in young patients with sporadic pituitary macroadenomas. Eur J Endocrinol. 2011;165:509–515.
   PubMed Web of Science ®Google Scholar
• Rostomyan L, Daly AF, Petrossians P, et al. Clinical and genetic characterization of pituitary gigantism: an international collaborative study in 208 patients. Endocr Relat Cancer. 2015;22:745–757.
   PubMed Web of Science ®Google Scholar
• Iacovazzo D, Caswell R, Bunce B, et al. Germline or somatic GPR101 duplication leads to X-linked acrogigantism: a clinico-pathological and genetic study. Acta Neuropathol Commun. 2016;4:56.
   PubMed Web of Science ®Google Scholar
• Gadelha MR, Kasuki L, Korbonits M. The genetic background of acromegaly. Pituitary. 2017;20:10–21.
   PubMed Web of Science ®Google Scholar
• Valdes-Socin H, Poncin J, Stevens V, et al. Familial isolated pituitary adenomas unrelated to MEN1 mutations: A follow-up of 27 patients. 10th meeting of the Belgian Endocrine Society. Ann Endocrinol (Paris). 2000;61:343.
   Google Scholar
• Daly AF, Rixhon M, Adam C, et al. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab. 2006;91:4769–4775.
   PubMed Web of Science ®Google Scholar
• Daly AF, Tichomirowa MA, Petrossians P, et al. Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study. J Clin Endocrinol Metab. 2010;95:E373–83.
   PubMed Web of Science ®Google Scholar
• Igreja S, Chahal HS, King P, et al. Characterization of aryl hydrocarbon receptor interacting protein (AIP) mutations in familial isolated pituitary adenoma families. Hum Mutat. 2010;31:950–960.
   PubMed Web of Science ®Google Scholar
• Beckers A, Aaltonen LA, Daly AF, et al. Familial isolated pituitary adenomas (FIPA) and the pituitary adenoma predisposition due to mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene. Endocr Rev. 2013;34:239–277.
   PubMed Web of Science ®Google Scholar
• Daly AF, Vanbellinghen JF, Khoo SK, et al. Aryl hydrocarbon receptor-interacting protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families. J Clin Endocrinol Metab. 2007;92:1891–1896.
   PubMed Web of Science ®Google Scholar
• Denes J, Swords F, Rattenberry E, et al. Heterogeneous genetic background of the association of pheochromocytoma/paraganglioma and pituitary adenoma: results from a large patient cohort. J Clin Endocrinol Metab. 2015;100:E531–41.
   PubMed Web of Science ®Google Scholar
• Xekouki P, Szarek E, Bullova P, et al. Pituitary adenoma with paraganglioma/pheochromocytoma (3PAs) and succinate dehydrogenase defects in humans and mice. J Clin Endocrinol Metab. 2015;100:E710–E719.
   PubMed Web of Science ®Google Scholar
• De Sousa SM, McCabe MJ, Wu K, et al. Germline variants in familial pituitary tumour syndrome genes are common in young patients and families with additional endocrine tumours. Eur J Endocrinol. 2017;176:635–644.
   PubMed Web of Science ®Google Scholar
• Iacovazzo D, Hernández-Ramírez LC, Korbonits M. Sporadic pituitary adenomas: the role of germline mutations and recommendations for genetic screening. Expert Rev Endocrinol Metab. 2017;12:143–153.
   PubMed Web of Science ®Google Scholar
• Hernández-Ramírez LC, Gabrovska P, Dénes J, et al. Landscape of familial isolated and young-onset pituitary adenomas: prospective diagnosis in AIP mutation carriers. J Clin Endocrinol Metab. 2015;100:E1242–54.
   PubMed Web of Science ®Google Scholar
• Marques P, Caimari F, Hernandez-Ramirez LC, et al. Significant benefits of AIP testing and clinical screening in familial isolated and young-onset pituitary tumors. J Clin Endocrinol Metab. 2020. DOI:10.1210/clinem/dgaa040.
   PubMedGoogle Scholar
• Xekouki P, Mastroyiannis SA, Avgeropoulos D, et al. Familial pituitary apoplexy as the only presentation of a novel AIP mutation. Endocr Relat Cancer. 2013;20:L11–L14.
   PubMed Web of Science ®Google Scholar
• Naves LA, Daly AF, Vanbellinghen JF, et al. Variable pathological and clinical features of a large Brazilian family harboring a mutation in the aryl hydrocarbon receptor-interacting protein gene. Eur J Endocrinol. 2007;157:383–391.
   PubMed Web of Science ®Google Scholar
• Leontiou CA, Gueorguiev M, van der Spuy J, et al. The role of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas. J Clin Endocrinol Metab. 2008;93:2390–2401.
   PubMed Web of Science ®Google Scholar
• Daly A, Rostomyan L, Betea D, et al. AIP-mutated acromegaly resistant to first-generation somatostatin analogs: long-term control with pasireotide LAR in two patients. Endocr Connect. 2019;8(4):367–377.
   Web of Science ®Google Scholar
• Williams F, Hunter S, Bradley L, et al. Clinical experience in the screening and management of a large kindred with familial isolated pituitary adenoma due to an aryl hydrocarbon receptor interacting protein (AIP) mutation. J Clin Endocrinol Metab. 2014;99:1122–1131.
   PubMed Web of Science ®Google Scholar
• Trivellin G, Daly AF, Faucz FR, et al. Gigantism and acromegaly due to Xq26 microduplications and GPR101 mutation. N Engl J Med. 2014;371:2363–2374.
   PubMed Web of Science ®Google Scholar
• Iacovazzo D, Korbonits M. Gigantism: X-linked acrogigantism and GPR101 mutations. Growth Horm IGF Res. 2016;30-31:64–69.
   PubMed Web of Science ®Google Scholar
• Beckers A, Lodish M, Giampaolo T, et al. X-linked acrogigantism (X-LAG) syndrome: clinical profile and therapeutic responses. Endocr Relat Cancer. 2015;22:353–367.
   PubMed Web of Science ®Google Scholar
• Gordon RJ, Bell J, Chung WK, et al. Childhood acromegaly due to X-linked acrogigantism: long term follow-up. Pituitary. 2016;19:560–564.
   PubMed Web of Science ®Google Scholar
• Trivellin G, Hernandez-Ramirez LC, Swan J, et al. An orphan G-protein-coupled receptor causes human gigantism and/or acromegaly: molecular biology and clinical correlations. Best Pract Res Clin Endocrinol Metab. 2018;32:125–140.
   PubMed Web of Science ®Google Scholar
• Wise-Oringer BK, Zanazzi GJ, Gordon RJ, et al. Familial X-linked acrogigantism: postnatal outcomes and tumor pathology in a prenatally diagnosed infant and his mother. J Clin Endocrinol Metab. 2019;104:4667–4675.
   PubMed Web of Science ®Google Scholar
• Daly AF, Yuan B, Fina F, et al. Somatic mosaicism underlies X-linked acrogigantism syndrome in sporadic male subjects. Endocr Relat Cancer. 2016;23:221–233.
   PubMed Web of Science ®Google Scholar
• Daly AF, Lysy PA, Desfilles C, et al. GHRH excess and blockade in X-LAG syndrome. Endocr Relat Cancer. 2016;23:161–170.
   PubMed Web of Science ®Google Scholar
• Rodd C, Millette M, Iacovazzo D, et al. Somatic GPR101 duplication causing X-Linked Acrogigantism (XLAG)-diagnosis and management. J Clin Endocrinol Metab. 2016;101:1927–1930.
   PubMed Web of Science ®Google Scholar
• Wermer P. Genetic aspects of adenomatosis of endocrine glands. Am J Med. 1954;16:363–371.
   PubMed Web of Science ®Google Scholar
• Thakker RV. Multiple endocrine neoplasia type 1 (MEN1) and type 4 (MEN4). Mol Cell Endocrinol. 2014;386:2–15.
   PubMed Web of Science ®Google Scholar
• Machens A, Schaaf L, Karges W, et al. Age-related penetrance of endocrine tumours in multiple endocrine neoplasia type 1 (MEN1): a multicentre study of 258 gene carriers. Clin Endocrinol (Oxf). 2007;67:613–622.
   PubMed Web of Science ®Google Scholar
• Thakker RV, Newey PJ, Walls GV, et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab. 2012;97:2990–3011.
   PubMed Web of Science ®Google Scholar
• Goudet P, Dalac A, Le Bras M, et al. MEN1 disease occurring before 21 years old: a 160-patient cohort study from the groupe d’etude des tumeurs endocrines. J Clin Endocrinol Metab. 2015;100:1568–1577.
   PubMed Web of Science ®Google Scholar
• Verges B, Boureille F, Goudet P, et al. Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study. J Clin Endocrinol Metab. 2002;87:457–465.
   PubMed Web of Science ®Google Scholar
• de Laat JM, Dekkers OM, Pieterman CR, et al. Long-term natural course of pituitary tumors in patients with MEN1: results from the DutchMEN1 Study Group (DMSG). J Clin Endocrinol Metab. 2015;100:3288–3296.
   PubMed Web of Science ®Google Scholar
• Trouillas J, Labat-Moleur F, Sturm N, et al. Pituitary tumors and hyperplasia in multiple endocrine neoplasia type 1 syndrome (MEN1): a case-control study in a series of 77 patients versus 2509 non-MEN1 patients. Am J Surg Pathol. 2008;32:534–543.
   PubMed Web of Science ®Google Scholar
• Pellegata NS, Quintanilla-Martinez L, Siggelkow H, et al. Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proc Natl Acad Sci USA. 2006;103:15558–15563.
   PubMed Web of Science ®Google Scholar
• Agarwal SK, Mateo CM, Marx SJ. Rare germline mutations in cyclin-dependent kinase inhibitor genes in multiple endocrine neoplasia type 1 and related states. J Clin Endocrinol Metab. 2009;94:1826–1834.
   PubMed Web of Science ®Google Scholar
• Georgitsi M. MEN-4 and other multiple endocrine neoplasias due to cyclin-dependent kinase inhibitors (p27(Kip1) and p18(INK4C)) mutations. Best Pract Res Clin Endocrinol Metab. 2010;24:425–437.
   PubMed Web of Science ®Google Scholar
• Frederiksen A, Rossing M, Hermann P, et al. Clinical features of multiple endocrine neoplasia type 4: novel pathogenic variant and review of published cases. J Clin Endocrinol Metab. 2019;104:3637–3646.
   PubMed Web of Science ®Google Scholar
• Xekouki P, Pacak K, Almeida M, et al. Succinate dehydrogenase (SDH) D subunit (SDHD) inactivation in a growth-hormone-producing pituitary tumor: a new association for SDH? J Clin Endocrinol Metab. 2012;97:E357–66.
   PubMed Web of Science ®Google Scholar
• O’Toole SM, Denes J, Robledo M, et al. 15 YEARS OF PARAGANGLIOMA: the association of pituitary adenomas and phaeochromocytomas or paragangliomas. Endocr Relat Cancer. 2015;22:T105–22.
   PubMed Web of Science ®Google Scholar
• Niemeijer ND, Papathomas TG, Korpershoek E, et al. Succinate Dehydrogenase (SDH)-deficient pancreatic neuroendocrine tumor expands the SDH-related tumor spectrum. J Clin Endocrinol Metab. 2015;100:E1386–93.
   PubMed Web of Science ®Google Scholar
• Niemeijer ND, Rijken JA, Eijkelenkamp K, et al. The phenotype of SDHB germline mutation carriers: a nationwide study. Eur J Endocrinol. 2017;177:115–125.
   PubMed Web of Science ®Google Scholar
• Dumitrescu CE, Collins MT. McCune-Albright syndrome. Orphanet J Rare Dis. 2008;3:12.
   PubMed Web of Science ®Google Scholar
• Weinstein LS, Shenker A, Gejman PV, et al. Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med. 1991;325:1688–1695.
   PubMed Web of Science ®Google Scholar
• Akintoye SO, Chebli C, Booher S, et al. Characterization of gsp-mediated growth hormone excess in the context of McCune-Albright syndrome. J Clin Endocrinol Metab. 2002;87:5104–5112.
   PubMed Web of Science ®Google Scholar
• Kovacs K, Horvath E, Thorner MO, et al. Mammosomatotroph hyperplasia associated with acromegaly and hyperprolactinemia in a patient with the McCune-Albright syndrome. A histologic, immunocytologic and ultrastructural study of the surgically-removed adenohypophysis. Virchows Arch A Pathol Anat Histopathol. 1984;403:77–86.
   PubMedGoogle Scholar
• Vortmeyer AO, Glasker S, Mehta GU, et al. Somatic GNAS mutation causes widespread and diffuse pituitary disease in acromegalic patients with McCune-Albright syndrome. J Clin Endocrinol Metab. 2012;97:2404–2413.
   PubMed Web of Science ®Google Scholar
• Galland F, Kamenicky P, Affres H, et al. McCune-Albright syndrome and acromegaly: effects of hypothalamopituitary radiotherapy and/or pegvisomant in somatostatin analog-resistant patients. J Clin Endocrinol Metab. 2006;91:4957–4961.
   PubMed Web of Science ®Google Scholar
• Stratakis CA, Kirschner LS, Carney JA. Clinical and molecular features of the Carney complex: diagnostic criteria and recommendations for patient evaluation. J Clin Endocrinol Metab. 2001;86:4041–4046.
   PubMed Web of Science ®Google Scholar
• Horvath A, Bertherat J, Groussin L, et al. Mutations and polymorphisms in the gene encoding regulatory subunit type 1-alpha of protein kinase A (PRKAR1A): an update. Hum Mutat. 2010;31:369–379.
   PubMed Web of Science ®Google Scholar
• Carney JA, Gordon H, Carpenter PC, et al. The complex of myxomas, spotty pigmentation, and endocrine overactivity. Medicine (Baltimore). 1985;64:270–283.
   PubMed Web of Science ®Google Scholar
• Stratakis CA, Carney JA, Lin JP, et al. Carney complex, a familial multiple neoplasia and lentiginosis syndrome. Analysis of 11 kindreds and linkage to the short arm of chromosome 2. J Clin Invest. 1996;97:699–705.
   PubMed Web of Science ®Google Scholar
• Kirschner LS, Carney JA, Pack SD, et al. Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex. Nat Genet. 2000;26:89–92.
   PubMed Web of Science ®Google Scholar
• Forlino A, Vetro A, Garavelli L, et al. PRKACB and Carney complex. N Engl J Med. 2014;370:1065–1067.
   PubMed Web of Science ®Google Scholar
• Salpea P, Horvath A, London E, et al. Deletions of the PRKAR1A Locus at 17q24.2-q24.3 in Carney complex: genotype-phenotype correlations and implications for genetic testing. J Clin Endocrinol Metab. 2014;99:E183–E188.
   PubMed Web of Science ®Google Scholar
• Bertherat J, Horvath A, Groussin L, et al. Mutations in regulatory subunit type 1A of cyclic adenosine 5ʹ-monophosphate-dependent protein kinase (PRKAR1A): phenotype analysis in 353 patients and 80 different genotypes. J Clin Endocrinol Metab. 2009;94:2085–2091.
   PubMed Web of Science ®Google Scholar
• Pack SD, Kirschner LS, Pak E, et al. Genetic and histologic studies of somatomammotropic pituitary tumors in patients with the “complex of spotty skin pigmentation, myxomas, endocrine overactivity and schwannomas” (Carney complex). J Clin Endocrinol Metab. 2000;85:3860–3865.
   PubMed Web of Science ®Google Scholar
• Ly KI, Blakeley JO. The diagnosis and management of neurofibromatosis type 1. Med Clin North Am. 2019;103:1035–1054.
   PubMed Web of Science ®Google Scholar
• Cambiaso P, Galassi S, Palmiero M, et al. Growth hormone excess in children with neurofibromatosis type-1 and optic glioma. Am J Med Genet A. 2017;173:2353–2358.
   PubMed Web of Science ®Google Scholar
• Hannah-Shmouni F, Demidowich AP, Rowell J, et al. Large pituitary gland with an expanding lesion in the context of neurofibromatosis 1. BMJ Case Rep. 2017.
   Google Scholar
• Hozumi K, Fukuoka H, Odake Y, et al. Acromegaly caused by a somatotroph adenoma in patient with neurofibromatosis type 1. Endocr J. 2019;66:853–857.
   PubMed Web of Science ®Google Scholar
• Bizzarri C, Bottaro G. Endocrine implications of neurofibromatosis 1 in childhood. Horm Res Paediatr. 2015;83:232–241.
   PubMed Web of Science ®Google Scholar
• Caimari F, Hernández-Ramírez LC, Dang MN, et al. Risk category system to identify pituitary adenoma patients with AIP mutations. J Med Genet. 2018;55:254–260.
   PubMed Web of Science ®Google Scholar
• Mete OK,M, Osamura RY, Trouillas J, et al. Somatotroph adenoma. In: Lloyd RVO,RY, Klöppel G, Rosai J, editors. WHO classification of tumours of endocrine organs. 4th ed., Vol. 10. World Health Organization International Agency for Research on Cancer; Lyon, France. 2017. p. 19–23.
   Google Scholar
• Larkin S, Reddy R, Karavitaki N, et al. Granulation pattern, but not GSP or GHR mutation, is associated with clinical characteristics in somatostatin-naive patients with somatotroph adenomas. Eur J Endocrinol. 2013;168:491–499.
   PubMed Web of Science ®Google Scholar
• Kiseljak-Vassiliades K, Carlson NE, Borges MT, et al. Growth hormone tumor histological subtypes predict response to surgical and medical therapy. Endocrine. 2015;49:231–241.
   PubMed Web of Science ®Google Scholar
• Iacovazzo D, Carlsen E, Lugli F, et al. Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study. Eur J Endocrinol. 2016;174:241–250.
   PubMed Web of Science ®Google Scholar
• Mazal PR, Czech T, Sedivy R, et al. Prognostic relevance of intracytoplasmic cytokeratin pattern, hormone expression profile, and cell proliferation in pituitary adenomas of akromegalic patients. Clin Neuropathol. 2001;20:163–171.
   PubMed Web of Science ®Google Scholar
• Obari A, Sano T, Ohyama K, et al. Clinicopathological features of growth hormone-producing pituitary adenomas: difference among various types defined by cytokeratin distribution pattern including a transitional form. Endocr Pathol. 2008;19:82–91.
   PubMed Web of Science ®Google Scholar
• Bakhtiar Y, Hirano H, Arita K, et al. Relationship between cytokeratin staining patterns and clinico-pathological features in somatotropinomae. Eur J Endocrinol. 2010;163:531–539.
   PubMed Web of Science ®Google Scholar
• Heck A, Ringstad G, Fougner SL, et al. Intensity of pituitary adenoma on T2-weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly. Clin Endocrinol (Oxf). 2012;77:72–78.
   PubMed Web of Science ®Google Scholar
• Kato M, Inoshita N, Sugiyama T, et al. Differential expression of genes related to drug responsiveness between sparsely and densely granulated somatotroph adenomas. Endocr J. 2012;59:221–228.
   PubMed Web of Science ®Google Scholar
• Brzana J, Yedinak CG, Gultekin SH, et al. Growth hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: a large single center experience. Pituitary. 2013;16:490–498.
   PubMed Web of Science ®Google Scholar
• Kiseljak-Vassiliades K, Xu M, Mills TS, et al. Differential somatostatin receptor (SSTR) 1-5 expression and downstream effectors in histologic subtypes of growth hormone pituitary tumors. Mol Cell Endocrinol. 2015;417:73–83.
   PubMed Web of Science ®Google Scholar
• Fougner SL, Lekva T, Borota OC, et al. The expression of E-cadherin in somatotroph pituitary adenomas is related to tumor size, invasiveness, and somatostatin analog response. J Clin Endocrinol Metab. 2010;95:2334–2342.
   PubMed Web of Science ®Google Scholar
• Lekva T, Berg JP, Fougner SL, et al. Gene expression profiling identifies ESRP1 as a potential regulator of epithelial mesenchymal transition in somatotroph adenomas from a large cohort of patients with acromegaly. J Clin Endocrinol Metab. 2012;97:E1506–E1514.
   PubMed Web of Science ®Google Scholar
• Corbetta S, Ballare E, Mantovani G, et al. Somatostatin receptor subtype 2 and 5 in human GH-secreting pituitary adenomas: analysis of gene sequence and mRNA expression. Eur J Clin Invest. 2001;31:208–214.
   PubMed Web of Science ®Google Scholar
• Taboada GF, Luque RM, Bastos W, et al. Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas. Eur J Endocrinol. 2007;156:65–74.
   PubMed Web of Science ®Google Scholar
• Taboada GF, Luque RM, Neto LV, et al. Quantitative analysis of somatostatin receptor subtypes (1-5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR. Eur J Endocrinol. 2008;158:295–303.
   PubMed Web of Science ®Google Scholar
• Casar-Borota O, Heck A, Schulz S, et al. Expression of SSTR2a, but not of SSTRs 1, 3, or 5 in somatotroph adenomas assessed by monoclonal antibodies was reduced by octreotide and correlated with the acute and long-term effects of octreotide. J Clin Endocrinol Metab. 2013;98:E1730–9.
   PubMed Web of Science ®Google Scholar
• Venegas-Moreno E, Vazquez-Borrego MC, Dios E, et al. Association between dopamine and somatostatin receptor expression and pharmacological response to somatostatin analogues in acromegaly. J Cell Mol Med. 2018;22:1640–1649.
   PubMed Web of Science ®Google Scholar
• Fischer T, Doll C, Jacobs S, et al. Reassessment of sst2 somatostatin receptor expression in human normal and neoplastic tissues using the novel rabbit monoclonal antibody UMB-1. J Clin Endocrinol Metab. 2008;93:4519–4524.
   PubMed Web of Science ®Google Scholar
• Gatto F, Feelders RA, van der Pas R, et al. Immunoreactivity score using an anti-sst2A receptor monoclonal antibody strongly predicts the biochemical response to adjuvant treatment with somatostatin analogs in acromegaly. J Clin Endocrinol Metab. 2013;98:E66–71.
   PubMed Web of Science ®Google Scholar
• Liu W, Xie L, He M, et al. Expression of somatostatin receptor 2 in somatotropinoma correlated with the short-term efficacy of somatostatin analogues. Int J Endocrinol. 2017;2017:9606985.
   PubMedGoogle Scholar
• Gatto F, Barbieri F, Arvigo M, et al. Biological and biochemical basis of the differential efficacy of first and second generation somatostatin receptor ligands in neuroendocrine neoplasms. Int J Mol Sci. 2019;20:3940.
   Web of Science ®Google Scholar
• Gatto F, Feelders RA, Franck SE, et al. In vitro head-to-head comparison between octreotide and pasireotide in GH-secreting pituitary adenomas. J Clin Endocrinol Metab. 2017;102:2009–2018.
   PubMed Web of Science ®Google Scholar
• Muhammad A, Coopmans EC, Gatto F, et al. Pasireotide responsiveness in acromegaly is mainly driven by somatostatin receptor subtype 2 expression. J Clin Endocrinol Metab. 2019;104:915–924.
   PubMed Web of Science ®Google Scholar
• Hofland LJ, van der Hoek J, van Koetsveld PM, et al. The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro. J Clin Endocrinol Metab. 2004;89:1577–1585.
   PubMed Web of Science ®Google Scholar
• Duran-Prado M, Saveanu A, Luque RM, et al. A potential inhibitory role for the new truncated variant of somatostatin receptor 5, sst5TMD4, in pituitary adenomas poorly responsive to somatostatin analogs. J Clin Endocrinol Metab. 2010;95:2497–2502.
   PubMed Web of Science ®Google Scholar
• Luque RM, Ibáñez-Costa A, Neto LV, et al. Truncated somatostatin receptor variant sst5TMD4 confers aggressive features (proliferation, invasion and reduced octreotide response) to somatotropinomas. Cancer Lett. 2015;359:299–306.
   PubMed Web of Science ®Google Scholar
• Ballare E, Persani L, Lania AG, et al. Mutation of somatostatin receptor type 5 in an acromegalic patient resistant to somatostatin analog treatment. J Clin Endocrinol Metab. 2001;86:3809–3814.
   PubMed Web of Science ®Google Scholar
• Filopanti M, Ballare E, Lania AG, et al. Loss of heterozygosity at the SS receptor type 5 locus in human GH- and TSH-secreting pituitary adenomas. J Endocrinol Invest. 2004;27:937–942.
   PubMed Web of Science ®Google Scholar
• Mantovani G, Treppiedi D, Giardino E, et al. Cytoskeleton actin-binding proteins in clinical behavior of pituitary tumors. Endocr Relat Cancer. 2019;26:R95–R108.
   PubMed Web of Science ®Google Scholar
• Coelho MCA, Vasquez ML, Wildemberg LE, et al. Molecular evidence and clinical importance of beta-arrestins expression in patients with acromegaly. J Cell Mol Med. 2018;22:2110–2116.
   PubMed Web of Science ®Google Scholar
• Peverelli E, Giardino E, Treppiedi D, et al. Filamin A (FLNA) plays an essential role in somatostatin receptor 2 (SST2) signaling and stabilization after agonist stimulation in human and rat somatotroph tumor cells. Endocrinology. 2014;155:2932–2941.
   PubMed Web of Science ®Google Scholar
• Gatto F, Biermasz NR, Feelders RA, et al. Low beta-arrestin expression correlates with the responsiveness to long-term somatostatin analog treatment in acromegaly. Eur J Endocrinol. 2016;174:651–662.
   PubMed Web of Science ®Google Scholar
• Gatto F, Feelders R, van der Pas R, et al. beta-Arrestin 1 and 2 and G protein-coupled receptor kinase 2 expression in pituitary adenomas: role in the regulation of response to somatostatin analogue treatment in patients with acromegaly. Endocrinology. 2013;154:4715–4725.
   PubMed Web of Science ®Google Scholar
• Theodoropoulou M, Zhang J, Laupheimer S, et al. Octreotide, a somatostatin analogue, mediates its antiproliferative action in pituitary tumor cells by altering phosphatidylinositol 3-kinase signaling and inducing Zac1 expression. Cancer Res. 2006;66:1576–1582.
   PubMed Web of Science ®Google Scholar
• Pagotto U, Arzberger T, Theodoropoulou M, et al. The expression of the antiproliferative gene ZAC is lost or highly reduced in nonfunctioning pituitary adenomas. Cancer Res. 2000;60:6794–6799.
   PubMed Web of Science ®Google Scholar
• Jaffrain-Rea ML, Angelini M, Gargano D, et al. Expression of aryl hydrocarbon receptor (AHR) and AHR-interacting protein in pituitary adenomas: pathological and clinical implications. Endocr Relat Cancer. 2009;16:1029–1043.
   PubMed Web of Science ®Google Scholar
• Kasuki Jomori de PL, Vieira NL, Armondi Wildemberg LE, et al. Low aryl hydrocarbon receptor-interacting protein expression is a better marker of invasiveness in somatotropinomas than Ki-67 and p53. Neuroendocrinology. 2011;94:39–48.
   PubMed Web of Science ®Google Scholar
• Kasuki L, Colli LM, Elias PC, et al. Resistance to octreotide LAR in acromegalic patients with high SSTR2 expression: analysis of AIP expression. Arq Bras Endocrinol Metabol. 2012;56:501–506. .
   PubMedGoogle Scholar
• Kasuki L, Neto L, Wildemberg LEA, et al. AIP expression in sporadic somatotropinomas is a predictor of the response to octreotide LAR therapy independent of SSTR2 expression. Endocr Relat Cancer. 2012;19:L25–L29.
   PubMed Web of Science ®Google Scholar
• Chahal HS, Trivellin G, Leontiou CA, et al. Somatostatin analogs modulate AIP in somatotroph adenomas: the role of the ZAC1 pathway. J Clin Endocrinol Metab. 2012;97:E1411–20.
   PubMed Web of Science ®Google Scholar
• Umahara M, Okada S, Ohshima K, et al. Glucose-dependent insulinotropic polypeptide induced growth hormone secretion in acromegaly. Endocr J. 2003;50:643–650.
   PubMed Web of Science ®Google Scholar
• Occhi G, Losa M, Albiger N, et al. The glucose-dependent insulinotropic polypeptide receptor is overexpressed amongst GNAS1 mutation-negative somatotropinomas and drives growth hormone (GH)-promoter activity in GH3 cells. J Neuroendocrinol. 2011;23:641–649.
   PubMed Web of Science ®Google Scholar
• Regazzo D, Losa M, Albiger NM, et al. The GIP/GIPR axis is functionally linked to GH-secretion increase in a significant proportion of gsp- somatotropinomas. Eur J Endocrinol. 2017;176:543–553.
   PubMed Web of Science ®Google Scholar
• Herman V, Fagin J, Gonsky R, et al. Clonal origin of pituitary adenomas. J Clin Endocrinol Metab. 1990;71:1427–1433.
   PubMed Web of Science ®Google Scholar
• Gadelha MR, Trivellin G, Hernández-Ramírez LC, et al. Genetics of pituitary adenomas. Front Horm Res. 2013;41:111–140.
   PubMed Web of Science ®Google Scholar
• Suhardja A, Kovacs K, Rutka J. Genetic basis of pituitary adenoma invasiveness: a review. J Neurooncol. 2001;52:195–204.
   PubMed Web of Science ®Google Scholar
• Ewing I, Pedder-Smith S, Franchi G, et al. A mutation and expression analysis of the oncogene BRAF in pituitary adenomas. Clin Endocrinol (Oxf). 2007;66:348–352.
   PubMed Web of Science ®Google Scholar
• Chamberlain CE, Scheel DW, McGlynn K, et al. Menin determines K-RAS proliferative outputs in endocrine cells. J Clin Invest. 2014;124:4093–4101.
   PubMed Web of Science ®Google Scholar
• Landis CA, Masters SB, Spada A, et al. GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumours. Nature. 1989;340:692–696.
   PubMed Web of Science ®Google Scholar
• Weinstein LS, Liu J, Sakamoto A, et al. Minireview: GNAS: normal and abnormal functions. Endocrinology. 2004;145:5459–5464.
   PubMed Web of Science ®Google Scholar
• Hayward BE, Barlier A, Korbonits M, et al. Imprinting of the G(s)alpha gene GNAS1 in the pathogenesis of acromegaly. J Clin Invest. 2001;107:R31–R36.
   PubMed Web of Science ®Google Scholar
• Mantovani G, Bondioni S, Lania AG, et al. Parental origin of Gsalpha mutations in the McCune-Albright syndrome and in isolated endocrine tumors. J Clin Endocrinol Metab. 2004;89:3007–3009.
   PubMed Web of Science ®Google Scholar
• Spada A, Arosio M, Bochicchio D, et al. Clinical, biochemical, and morphological correlates in patients bearing growth hormone-secreting pituitary-tumors with or without constitutively active adenylyl cyclase. J Clin Endocrinol Metab. 1990;71:1421–1426.
   PubMed Web of Science ®Google Scholar
• Buchfelder M, Fahlbusch R, Merz T, et al. Clinical correlates in acromegalic patients with pituitary tumors expressing GSP oncogenes. Pituitary. 1999;1:181–185.
   PubMedGoogle Scholar
• Mayr B, Buslei R, Theodoropoulou M, et al. Molecular and functional properties of densely and sparsely granulated GH-producing pituitary adenomas. Eur J Endocrinol. 2013;169:391–400.
   PubMed Web of Science ®Google Scholar
• Efstathiadou ZA, Bargiota A, Chrisoulidou A, et al. Impact of gsp mutations in somatotroph pituitary adenomas on growth hormone response to somatostatin analogs: a meta-analysis. Pituitary. 2015;18:861–867.
   PubMed Web of Science ®Google Scholar
• Valimaki N, Demir H, Pitkanen E, et al. Whole-genome sequencing of Growth Hormone (GH)-secreting pituitary adenomas. J Clin Endocrinol Metab. 2015;100:3918–3927.
   PubMed Web of Science ®Google Scholar
• Ronchi CL, Peverelli E, Herterich S, et al. Landscape of somatic mutations in sporadic GH-secreting pituitary adenomas. Eur J Endocrinol. 2016;174(3):363–372.
   PubMed Web of Science ®Google Scholar
• Hage M, Viengchareun S, Brunet E, et al. Genomic alterations and complex subclonal architecture in sporadic GH-secreting pituitary adenomas. J Clin Endocrinol Metab. 2018;103:1929–1939.
   PubMed Web of Science ®Google Scholar
• Valimaki N, Schalin-Jantti C, Karppinen A, et al. Genetic and epigenetic characterization of growth hormone-secreting pituitary tumors. Mol Cancer Res. 2019;17:2432–2443.
   PubMed Web of Science ®Google Scholar
• Salomon MP, Wang X, Marzese DM, et al. The epigenomic landscape of pituitary adenomas reveals specific alterations and differentiates among acromegaly, cushing’s disease and endocrine-inactive subtypes. Clin Cancer Res. 2018;24:4126–4136.
   PubMed Web of Science ®Google Scholar